FindMyKOL

Richard Bockman, MD

Basic profile

Hospital for Special Surgery

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding1985–1992Why? →

Richard Bockman is an Endocrinology/Metabolic physician affiliated with Hospital for Special Surgery. OpenAlex indexes 103 publications with 4,111 citations (h-index 37).

Overview

Scholarship

indexed output and impact (OpenAlex)
103publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

4,111citations

Citations across these publications.

37h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
18companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 1985–1992

Federally funded research awards.

View funding ↓

Industry payments

18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen Inc.
    Program year202514 payments
    $601
  • Astellas Pharma US Inc
    Program year202510 payments
    $322
  • KYOWA KIRIN, INC.
    Program year202511 payments
    $196
All 38 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    74.3%
    RANK Ligand Inhibitor70.8%
    Denosumab91%Prolia9%
    Part D + Part B≥52 patients
    Bisphosphonates3.5%
    Risedronate Sodium100%
    Part D≥13 patients
  • Hormonal (systemic)

    17%
    l-Thyroxine12.4%
    Levothyroxine Sodium64%Synthroid36%
    Part D≥30 patients
    Parathyroid Hormone-Related Peptide Analog2.7%
    Tymlos100%
    Part D<11 patients

    + 1 more class in this area

  • Genitourinary & hormones

    6.4%
    Estrogen Agonist/Antagonist6.4%
    Raloxifene Hcl100%
    Part D≥24 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

2 NIH research awards on record, funded 1985–1992 per NIH RePORTER. The latest:

All 9 award records: search, sort and filter.Explore →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”